| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Nanexa AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 0.063 |
| 52 Week High | SEK 0.31 |
| 52 Week Low | SEK 0.028 |
| Beta | 1.55 |
| 11 Month Change | -11.33% |
| 3 Month Change | 33.76% |
| 1 Year Change | -76.90% |
| 33 Year Change | -87.53% |
| 5 Year Change | n/a |
| Change since IPO | -94.11% |
Recent News & Updates
Recent updates
Shareholder Returns
| 40M | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | 15.1% | 3.7% | 0.09% |
| 1Y | -76.9% | 4.1% | 3.1% |
Return vs Industry: 40M underperformed the German Medical Equipment industry which returned 4.1% over the past year.
Return vs Market: 40M underperformed the German Market which returned 3.1% over the past year.
Price Volatility
| 40M volatility | |
|---|---|
| 40M Average Weekly Movement | 30.6% |
| Medical Equipment Industry Average Movement | 4.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.7% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 40M's share price has been volatile over the past 3 months.
Volatility Over Time: 40M's weekly volatility (31%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 19 | David Westberg | www.nanexa.com |
Nanexa AB (publ) operates as a nanotechnology drug delivery company. It operates PharmaShell, a nanobased drug delivery platform that is an atomic layer deposition. The company also develops NEX-18, which drives the development of a PharmaShell that targets myelodysplastic Syndrome and Acute Myeloid Leukemia; NEX-20 for the treatment of multiple myeloma; and NEX-22 for the treatment of type 2 diabetes.
Nanexa AB (publ) Fundamentals Summary
| 40M fundamental statistics | |
|---|---|
| Market cap | €10.85m |
| Earnings (TTM) | -€6.22m |
| Revenue (TTM) | €5.26m |
2.1x
P/S Ratio-1.7x
P/E RatioIs 40M overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 40M income statement (TTM) | |
|---|---|
| Revenue | SEK 59.73m |
| Cost of Revenue | SEK 25.63m |
| Gross Profit | SEK 34.10m |
| Other Expenses | SEK 104.72m |
| Earnings | -SEK 70.62m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 27, 2024
| Earnings per share (EPS) | -0.52 |
| Gross Margin | 57.09% |
| Net Profit Margin | -118.23% |
| Debt/Equity Ratio | 2.0% |
How did 40M perform over the long term?
See historical performance and comparison